ResTORbio stock jumps after anti-infection drug shows promise

Shares of Boston-based resTORbio jumped Wednesday after the company reported that one of its experimental drugs helped prevent respiratory tract infections among elderly patients in a mid-stage trial. ResTORbio (Nasdaq: TORC), which raised $85 million in its January IPO, is developing drugs to offset aging-related diseases, including potentially deadly respiratory tract infections. The trial data released Wednesday showed that the pill, called RTB101, caused a 31 percent reduction in the percen tage…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news